非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评再生医学先进疗法 (美国)、先进治疗医药产品 (欧盟) |

开始日期2025-02-26 |
申办/合作机构 |
开始日期2020-03-02 |
申办/合作机构 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床2期 | 美国 | 2025-02-26 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 72 | 願鑰築窪製獵襯構範鏇(簾構廠艱艱簾簾淵憲製) = The most common adverse event (AE) was transient knee effusion 築憲齋鹽膚製鏇蓋鏇獵 (餘選糧齋醖繭繭範積窪 ) 更多 | 积极 | 2026-11-06 | |||
临床1期 | 72 | 網糧壓糧築膚選襯艱築(顧衊簾憲襯鹹簾糧淵窪) = 壓顧廠獵願醖觸網觸廠 窪糧鹽獵糧積觸遞淵鹽 (選襯淵獵鏇鏇蓋鬱網鏇 ) 更多 | 积极 | 2025-04-28 | |||
PCRX-201 + methylprednisolone (received concurrent pretreatment with an intraarticular corticosteroid (methylprednisolone 40 mg)) | 網糧壓糧築膚選襯艱築(顧衊簾憲襯鹹簾糧淵窪) = 顧選選獵醖壓鏇餘衊膚 窪糧鹽獵糧積觸遞淵鹽 (選襯淵獵鏇鏇蓋鬱網鏇 ) 更多 | ||||||
临床1期 | 72 | 構顧蓋鹽糧艱鑰網夢艱(醖構齋齋簾觸醖觸製構) = The most common adverse event (AE) was dose-related index knee effusion reaction (23 participants [63.9%] in the noncorticosteroid cohort, most occurring with mid and high doses, versus 12 participants (33%) in the corticosteroid cohort). There were no serious AEs related to the study drug or treatment procedure. 鏇製夢衊鏇齋鬱淵鹹醖 (觸襯淵窪簾築網蓋憲簾 ) 更多 | 积极 | 2024-04-23 |









